SG11201700819QA - An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use - Google Patents
An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and useInfo
- Publication number
- SG11201700819QA SG11201700819QA SG11201700819QA SG11201700819QA SG11201700819QA SG 11201700819Q A SG11201700819Q A SG 11201700819QA SG 11201700819Q A SG11201700819Q A SG 11201700819QA SG 11201700819Q A SG11201700819Q A SG 11201700819QA SG 11201700819Q A SG11201700819Q A SG 11201700819QA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- monoclonal antibody
- antigen binding
- binding fragment
- ctla4 monoclonal
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410377352.9A CN105296433B (zh) | 2014-08-01 | 2014-08-01 | 一种ctla4抗体、其药物组合物及其用途 |
| PCT/CN2015/085721 WO2016015675A1 (zh) | 2014-08-01 | 2015-07-31 | 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700819QA true SG11201700819QA (en) | 2017-03-30 |
Family
ID=55194268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700819QA SG11201700819QA (en) | 2014-08-01 | 2015-07-31 | An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use |
Country Status (39)
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| WO2016196237A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| CA2993432A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| CN107400166A (zh) | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| KR102531889B1 (ko) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018068182A1 (en) * | 2016-10-10 | 2018-04-19 | Crown Bioscience (Taicang) Inc. | Novel anti-ctla4 antibodies |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| PL3551660T3 (pl) | 2016-12-07 | 2024-02-26 | Agenus Inc. | Przeciwciała anty-ctla-4 i sposoby ich stosowania |
| CN108124445B (zh) * | 2017-03-15 | 2021-05-04 | 苏州银河生物医药有限公司 | Ctla4抗体、其药物组合物及其用途 |
| EP3600426A4 (en) * | 2017-03-31 | 2021-01-20 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND AN ANTI-CTLA4 ANTIBODY |
| JP2020518598A (ja) * | 2017-05-02 | 2020-06-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法 |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN116478289A (zh) * | 2017-05-19 | 2023-07-25 | 上海药明生物技术有限公司 | 一种新的ctla-4单克隆抗体 |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| MX2019013648A (es) * | 2017-05-19 | 2021-01-08 | Wuxi Biologics Shanghai Co Ltd | Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4). |
| CN107325181A (zh) * | 2017-07-05 | 2017-11-07 | 无锡傲锐东源生物科技有限公司 | 抗ctla4蛋白单克隆抗体及其用途 |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| MX2020003132A (es) * | 2017-09-21 | 2020-07-28 | Eucure Beijing Biopharma Co Ltd | Anticuerpos anti-ctla4 y usos de los mismos. |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| EP3768721A4 (en) * | 2018-03-19 | 2021-12-29 | Wuxi Biologics Ireland Limited. | Novel anti-ctla-4 antibody polypeptide |
| CN109336975B (zh) * | 2018-04-18 | 2022-05-13 | 中国科学院微生物研究所 | 一种靶向pd-1的肿瘤抑制性抗体及其应用 |
| JP7359785B2 (ja) * | 2018-06-05 | 2023-10-11 | 江蘇康寧杰瑞生物制薬有限公司 | 二量体及びその使用 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| CN110760002A (zh) * | 2018-07-25 | 2020-02-07 | 南京金斯瑞生物科技有限公司 | 人源化抗人ctla4单克隆抗体及其制备方法和用途 |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| BR112021012037A2 (pt) | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula anti-pd-1/il-7 bifuncional |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| CN110256561B (zh) * | 2019-06-13 | 2021-04-16 | 东大生物技术(苏州)有限公司 | 一组ctla-4单克隆抗体及其医药用途 |
| CN110256563A (zh) * | 2019-07-05 | 2019-09-20 | 石河子大学 | Ctla-4纳米抗体、制备方法及其应用 |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| US20230118596A1 (en) * | 2020-03-05 | 2023-04-20 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof |
| WO2021178611A1 (en) * | 2020-03-05 | 2021-09-10 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody |
| KR20220166795A (ko) * | 2020-04-13 | 2022-12-19 | 바이오션, 인코포레이티드 | Ctla4에 결합하는 항체 및 이의 용도 |
| CA3186777A1 (en) * | 2020-06-11 | 2021-12-16 | Nantbio, Inc. | Anti-ctla4 monoclonal antibodies and chimeric antigen receptors |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CN113980130B (zh) * | 2020-07-27 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化cd37和双特异性cd19-人源化cd37 car-t细胞 |
| CN112079926A (zh) * | 2020-09-17 | 2020-12-15 | 北京华大蛋白质研发中心有限公司 | 抗人ctla4单克隆抗体及其应用 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| KR20230165276A (ko) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도 |
| US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
| CA3213917A1 (en) | 2021-04-09 | 2022-10-13 | Nicolas Poirier | New scaffold for bifunctional molecules with improved properties |
| JP2024525475A (ja) | 2021-06-29 | 2024-07-12 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションを促進するように操作された免疫細胞及びその使用 |
| CN117069850B (zh) * | 2021-12-20 | 2025-02-14 | 南京诺唯赞检测技术有限公司 | 一种vce的单克隆抗体及其制备方法 |
| CN118541390A (zh) * | 2022-01-30 | 2024-08-23 | 百奥赛图(北京)医药科技股份有限公司 | 抗ctla4/ox40双特异性抗体及其用途 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| TW202426499A (zh) * | 2022-09-16 | 2024-07-01 | 大陸商同潤生物醫藥(上海)有限公司 | 具有pH依賴性的抗CTLA4抗體或抗原結合片段 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US682736A (en) | 1900-08-02 | 1901-09-17 | James C Owen | Oil-can. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| KR19990008070A (ko) | 1995-04-27 | 1999-01-25 | 게일 케이.노톤 | 합성 또는 천연 혈관 식피의 멸균, 내이식, 배양, 보존, 수송및 검사를 위한 장치 및 방법 |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US7122615B1 (en) | 1998-09-10 | 2006-10-17 | Rutgers, The State University Of New Jersey | Polyanhydrides with therapeutically useful degradation products |
| PT1141028E (pt) | 1998-12-23 | 2010-05-04 | Pfizer | Anticorpos monoclonais humanos contra ctla-4 |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) * | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| NZ530212A (en) * | 2001-06-13 | 2006-09-29 | Genmab As | An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) |
| IL164287A0 (en) | 2002-04-12 | 2005-12-18 | Medarex Inc | Methods of treatment using ctla-4 antibodies |
| WO2003099890A2 (en) | 2002-05-24 | 2003-12-04 | Castrol Limited | Preparation of monomers for grafting to polyolefins, and lubricating oil compositions containing grafted copolymer |
| PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
| JP2006500931A (ja) | 2002-09-30 | 2006-01-12 | ファイザー・プロダクツ・インク | 高レベルのヒト配列抗体を産生するハイブリドーマ |
| US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| JP4662473B2 (ja) * | 2002-10-17 | 2011-03-30 | ゲンマブ エー／エス | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
| CA2560919A1 (en) | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
| DE102004063494A1 (de) * | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
| JP2006249083A (ja) * | 2005-03-08 | 2006-09-21 | Pharmacia & Upjohn Co Llc | 抗ｍ−ｃｓｆ抗体組成物 |
| NZ562949A (en) | 2005-04-11 | 2009-05-31 | Medarex Inc | Protein purification using HCIC and ion exchange chromatography |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| CN101074264B (zh) * | 2006-05-17 | 2011-08-17 | 上海抗体药物国家工程研究中心有限公司 | 一种重组抗ctla4单克隆抗体及其制备方法和用途 |
| EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| CA2777226A1 (en) | 2009-10-12 | 2011-04-21 | Pfizer Inc. | Cancer treatment |
| HUE035508T2 (en) | 2009-11-17 | 2018-05-02 | Squibb & Sons Llc | Methods for enhanced protein production |
| CN102134276A (zh) * | 2010-01-22 | 2011-07-27 | 上海抗体药物国家工程研究中心有限公司 | 一种抗ctla-4嵌合抗体 |
| JP2014500004A (ja) * | 2010-09-24 | 2014-01-09 | オンコス セラピュティックス オサケ ユキチュア | 抗ｃｔｌａ−４モノクローナル抗体をコードする腫瘍溶解性アデノウイルスベクター |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| WO2013003761A1 (en) | 2011-06-30 | 2013-01-03 | Genzyme Corporation | Inhibitors of t-cell activation |
| US20150079100A1 (en) | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
| SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US8844207B2 (en) | 2012-06-04 | 2014-09-30 | Mity-Lite, Inc. | Portable dance floor panel with floating magnet retention system |
| CN102801616B (zh) | 2012-08-02 | 2015-04-15 | 华为技术有限公司 | 报文发送和接收的方法、装置和系统 |
| EP2759305A1 (en) | 2013-01-24 | 2014-07-30 | Thrombotargets Europe, S.L. | Hemostatic compositions |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| CN106255510A (zh) | 2014-03-05 | 2016-12-21 | 百时美施贵宝公司 | 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌 |
| BR112016026559A8 (pt) | 2014-05-15 | 2021-07-13 | Bristol Myers Squibb Co | uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| BR112017010101A2 (pt) | 2014-12-16 | 2018-01-02 | Bristol Myers Squibb Co | uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central |
| CN104479019B (zh) | 2014-12-26 | 2020-07-21 | 上海复宏汉霖生物技术股份有限公司 | 一种抗ctla-4人源抗体 |
| JP6932649B2 (ja) | 2015-02-16 | 2021-09-08 | ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ | Ｃｌ及び／又はｃｈ１が突然変異された薬剤コンジュゲーションのための抗体 |
| WO2016183469A1 (en) | 2015-05-13 | 2016-11-17 | Robert Kirken | Anti-ctla-4 blockade |
| US20210206854A1 (en) | 2016-01-27 | 2021-07-08 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
-
2014
- 2014-08-01 CN CN201410377352.9A patent/CN105296433B/zh active Active
-
2015
- 2015-07-31 TN TN2017000010A patent/TN2017000010A1/en unknown
- 2015-07-31 CN CN202211206595.7A patent/CN115960232A/zh active Pending
- 2015-07-31 PL PL15827441T patent/PL3176181T3/pl unknown
- 2015-07-31 UA UAA201701943A patent/UA119570C2/uk unknown
- 2015-07-31 MA MA40474A patent/MA40474B1/fr unknown
- 2015-07-31 MD MDA20170022A patent/MD4795C1/ro active IP Right Grant
- 2015-07-31 NZ NZ729158A patent/NZ729158A/en unknown
- 2015-07-31 WO PCT/CN2015/085721 patent/WO2016015675A1/zh active Application Filing
- 2015-07-31 EA EA201790288A patent/EA036396B1/ru not_active IP Right Cessation
- 2015-07-31 GE GEAP201514437A patent/GEP20207166B/en unknown
- 2015-07-31 ES ES15827441T patent/ES2857509T3/es active Active
- 2015-07-31 MA MA055868A patent/MA55868A/fr unknown
- 2015-07-31 US US15/500,744 patent/US10449251B2/en active Active
- 2015-07-31 RS RS20210312A patent/RS61590B1/sr unknown
- 2015-07-31 CA CA2956000A patent/CA2956000C/en active Active
- 2015-07-31 SI SI201531555T patent/SI3176181T1/sl unknown
- 2015-07-31 AP AP2017009762A patent/AP2017009762A0/en unknown
- 2015-07-31 EP EP15827441.5A patent/EP3176181B1/en active Active
- 2015-07-31 DK DK15827441.5T patent/DK3176181T3/da active
- 2015-07-31 KR KR1020177005688A patent/KR102017396B1/ko active Active
- 2015-07-31 LT LTEP15827441.5T patent/LT3176181T/lt unknown
- 2015-07-31 MY MYPI2017000162A patent/MY192822A/en unknown
- 2015-07-31 PT PT158274415T patent/PT3176181T/pt unknown
- 2015-07-31 HU HUE15827441A patent/HUE053719T2/hu unknown
- 2015-07-31 PE PE2017000155A patent/PE20170772A1/es unknown
- 2015-07-31 SG SG11201700819QA patent/SG11201700819QA/en unknown
- 2015-07-31 PH PH1/2017/500190A patent/PH12017500190B1/en unknown
- 2015-07-31 HR HRP20210448TT patent/HRP20210448T1/hr unknown
- 2015-07-31 EP EP20216429.9A patent/EP3858861A1/en active Pending
- 2015-07-31 CN CN201580040171.XA patent/CN106687479B/zh active Active
- 2015-07-31 MX MX2017001446A patent/MX387685B/es unknown
- 2015-07-31 AU AU2015295936A patent/AU2015295936C1/en active Active
- 2015-07-31 JP JP2017525666A patent/JP6514774B2/ja active Active
- 2015-08-31 CR CR20170033A patent/CR20170033A/es unknown
-
2017
- 2017-01-23 ZA ZA2017/00528A patent/ZA201700528B/en unknown
- 2017-01-26 IL IL250321A patent/IL250321B/en active IP Right Grant
- 2017-01-27 CO CONC2017/0000754A patent/CO2017000754A2/es unknown
- 2017-01-31 MX MX2021013586A patent/MX2021013586A/es unknown
- 2017-01-31 NI NI201700008A patent/NI201700008A/es unknown
- 2017-01-31 CL CL2017000250A patent/CL2017000250A1/es unknown
- 2017-02-01 DO DO2017000031A patent/DOP2017000031A/es unknown
- 2017-03-01 EC ECIEPI201712781A patent/ECSP17012781A/es unknown
-
2018
- 2018-10-11 AU AU2018247270A patent/AU2018247270A1/en not_active Abandoned
-
2019
- 2019-02-28 JP JP2019036646A patent/JP6783886B2/ja active Active
- 2019-09-05 US US16/562,236 patent/US11291720B2/en active Active
-
2021
- 2021-03-08 CY CY20211100197T patent/CY1124190T1/el unknown
-
2022
- 2022-03-15 US US17/695,592 patent/US20230064544A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250321B (en) | Anti-ctla4 monoclonal antibody or its conjugated antigen residue, pharmaceutical composition and uses | |
| IL269593A (en) | Anti-ILT4 antibodies and antigen-binding fragments | |
| EP3378871A4 (en) | PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF | |
| IL259643A (en) | Antibodies and antibody fragments for site-specific conjugation | |
| PT3476399T (pt) | Anticorpo lag-3, fragmento de ligação a antigénio deste e aplicação farmacêutica deste | |
| LT3505535T (lt) | Monokloninis antikūnas prieš pd1, jo farmacinė kompozicija ir panaudojimas | |
| IL251938A0 (en) | Antibodies against CS1 and antibody-drug conjugates | |
| HUE048939T2 (hu) | Human B sejt érési antigén elleni monoklonális antitestek (BCMA) | |
| DK3182999T3 (da) | Anti-lag3-antistoffer og antigenbindingsfragmenter | |
| IL262404A (en) | Antibodies, antibody fragments, and their immunosuppressants against ror2 and their uses | |
| IL247873A0 (en) | Peptides and antibodies derived from the cdr3 region of the t-cell receptor | |
| RS61158B1 (sr) | Anti-sklerostin antitelo, antigen vezujući fragment i njegova medicinska upotreba | |
| ZA202001807B (en) | Il-5 antibody, antigen binding fragment thereof, and medical application therefor | |
| EP3209686A4 (en) | Monoclonal anti-gpc-1 antibodies and uses thereof | |
| ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
| GB201415714D0 (en) | Antibodies and antigen binding fragments thereof | |
| GB201715149D0 (en) | IL-ß binding antibody | |
| HK1234073A1 (en) | Anti-hepatitis c antibodies and antigen binding fragments thereof | |
| HK1246314A1 (en) | Antibodies and chimeric antigen receptors specific for ror1 |